Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Clinical trial NCT02475213 · COMPLETED

Trial details

NCT number: NCT02475213
Sponsor: MacroGenics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Head and Neck Cancer Non Small Cell Lung Cancer Urothelial Carcinoma

Start date: 2015-07-01
Primary completion: 2021-08-18
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.